Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Forster, Rachel; Stewart, Marlene

doi:10.1002/14651858.cd004179.pub2

Cited by 73 publications

(68 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While the role of extended prophylaxis in minimally invasive gynecologic surgery remains debated, VTE rates are in the range of 0.5% or less and do not appear to be modulated based on whether or not prophylaxis was given 77–80. Additionally, although direct-acting oral anticoagulants are a recommended therapy for VTE when diagnosed in patients with active cancer,81–83 the role for direct-acting oral anticoagulants for post-operative prophylaxis is currently limited to orthopedic surgery literature and requires further study in gynecologic surgery 84…”

Section: Resultsmentioning

confidence: 99%

Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations—2019 update

Nelson¹,

Bakkum-Gamez

Kalogera

et al. 2019

Int J Gynecol Cancer

514

364

View full text Add to dashboard Cite

BackgroundThis is the first updated Enhanced Recovery After Surgery (ERAS) Society guideline presenting a consensus for optimal perioperative care in gynecologic/oncology surgery.MethodsA database search of publications using Embase and PubMed was performed. Studies on each item within the ERAS gynecologic/oncology protocol were selected with emphasis on meta-analyses, randomized controlled trials, and large prospective cohort studies. These studies were then reviewed and graded according to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system.ResultsAll recommendations on ERAS protocol items are based on best available evidence. The level of evidence for each item is presented accordingly.ConclusionsThe updated evidence base and recommendation for items within the ERAS gynecologic/oncology perioperative care pathway are presented by the ERAS® Society in this consensus review.

show abstract

Section: Resultsmentioning

confidence: 99%

Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations—2019 update

Nelson¹,

Bakkum-Gamez

Kalogera

et al. 2019

Int J Gynecol Cancer

514

364

View full text Add to dashboard Cite

show abstract

“…To complicate matters even further, there will be patients who will develop thrombosis, despite taking prophylaxis. As an example, in a Cochrane review on thromboprophylaxis after major orthopedic surgery, 2% of patients developed venous thrombosis despite thromboprophylaxis with low‐molecular‐weight heparin . In addition, in the POT‐KAST and POT‐CAST trials low‐dosed thromboprophylaxis was compared with no thromboprophylaxis for preventing symptomatic venous thrombosis in patients who underwent knee arthroscopy for the duration of eight days and for the full period of immobilization patients with casting of the low leg, respectively.…”

Section: How Can We Further Improve?mentioning

confidence: 99%

Current and future burden of venous thrombosis: Not simply predictable

Scheres

Lijfering

Cannegieter

2018

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Essentials The incidence of venous thrombosis has remained stable over the past decade.Risk factors and diagnostic and prophylaxis strategies are determinants of the overall incidence.Given current trends of the determinants, we are making progress in reducing the burden.More progress can be made by implementing validated risk assessment models. Venous thrombosis is a major contributor to the global disease burden. In this review we aim to answer two important questions: (1) are we making progress in reducing this disease burden and (2) how can we further improve? To answer these questions, we first evaluated the disease burden, that is, the incidence of first venous thrombosis over the past decade(s) and discuss its most important determinants. We found that the incidence of first venous thrombosis remained relatively unchanged, despite an increase in risk factor prevalence and a rise in identification of subsegmental pulmonary emboli due to enhanced image quality and utilization. This is, however, balanced by improved thromboprophylaxis strategies, resulting in an overall unchanged venous thrombosis incidence. We can further improve by developing, validating, and implementing risk assessment strategies, allowing us to identify persons at high or low risk in whom thromboprophylaxis can be provided or withheld, respectively.

show abstract

“…On the whole, extended pharmacological thromboprophylaxis is recommended in patients undergoing major orthopaedic surgery, from the day of surgery, in absence of bleeding [9]. There are no clear references regarding the thrombotic risk in adolescence under orthopaedic surgery and no one in subjects with FV deficiency.…”

Section: Discussionmentioning

confidence: 99%

Hip Replacement Surgery in 14-Year-Old Girl with Factor V Deficiency: Haemostatic Treatment and Thromboprophylaxis

Mingot‐Castellano

Pérez-Núñez

Baeza-Montañez

2016

Case Reports in Hematology

View full text Add to dashboard Cite

Factor V (FV) is a pivotal coagulation factor present in plasma and platelets. It plays an essential role in secondary haemostasis acting as a cofactor in the prothrombinase complex, catalysing the conversion of prothrombin to thrombin. There is little evidence on the management of mayor orthopaedic surgery in paediatric or adolescents subjects with this coagulopathy and almost no information about thromboprophylaxis in these situations. We report a case of a hip replacement in a 14-year-old girl with moderate FV deficiency (0.07 IU mL−1). As haemostatic replacement, inactivated fresh frozen plasma (FFP) was transfused at doses of 600 mL (15 mL kg−1, 45 kg weight) 2 hours before surgery and then sequential FFP infusions of 250 mL (7 mL kg−1) every 12 hours for 7 days. Plasma factor VIII, von Willebrand factor antigen, and von Willebrand ristocetin cofactor were monitored to avoid supranormal levels. Since the patient was sexually mature (Marshall and Tanner stage 5) with the hormone replacement therapy, she was immobilized and the surgery was considered as a high thrombotic risk. Thus, low molecular weight heparin was administered at doses of intermediate risk (Enoxaparin 20 mg daily, by weight) after finishing the daily infusion of plasma: 24 hours and during the 7 days after intervention. No tranexamic acid was used. No haemorrhagic or thrombotic adverse event was described.

show abstract

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Cited by 73 publications

References 61 publications

Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations—2019 update

Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations—2019 update

Current and future burden of venous thrombosis: Not simply predictable

Hip Replacement Surgery in 14-Year-Old Girl with Factor V Deficiency: Haemostatic Treatment and Thromboprophylaxis

Contact Info

Product

Resources

About